Group 1 - Company shares of EnGene Biotech-B (09606) opened over 4% higher, currently up 4.63% at 380 HKD, with a trading volume of 7.506 million HKD [1] - EnGene Biotech-B announced that starting from September 8, 2025, its shares will be included in the Hang Seng Composite Index and added to the eligible securities list for the Shanghai-Hong Kong Stock Connect, indicating strong market recognition of the company's performance and value [1] - The inclusion in the Hang Seng Composite Index and the Shanghai-Hong Kong Stock Connect is expected to expand the company's investor base and potentially increase the trading liquidity of its shares [1] Group 2 - The company plans to communicate with the National Medical Products Administration regarding the submission of the Biologics License Application (BLA) for DB-1303/BNT323 [2] - DB-1303/BNT323 is a clinical-stage HER2 ADCD candidate drug currently undergoing two ongoing registration clinical trials and another potential global registration study [2] - The company's partner, BioNTech SE, is preparing to submit the drug's BLA in 2025 [2]
港股异动 | 映恩生物-B(09606)高开逾4% 获纳入恒生综合指数成份股 乳腺癌新药III期临床达主要终点